Cognition Therapeutics, Inc. Share Price

Cognition Therapeutics, Inc. Share Price

NASDAQ: CGTX | Micro Cap
$0.73
-$0.01 (-1.36%) Last updated on 30 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Cognition Therapeutics, Inc. Stock Performance

Open
$0.74
Prev. Close
$0.74
Circuit Range
N/A
Day Range
$0.72 - $0.74
Year Range
$0.55 - $1.82
Volume
1,648
Average Traded
$0.73

Cognition Therapeutics, Inc. Share Price Today

As of 30 October 2026, Cognition Therapeutics, Inc.'s share price is $0.73. The stock opened at $0.74, compared to its previous close of $0.74. During today's trading session, Cognition Therapeutics, Inc.'s share price traded between $0.72 and $0.74, with an average price of $0.73. Over the past 52 weeks, the stock has recorded a high of $1.82 and a low of $0.55. In terms of performance, Cognition Therapeutics, Inc.'s share price has declined by 41.94% over the last six months and is down 59.08% on a year-on-year basis.

Cognition Therapeutics, Inc. Share Price Chart

Line chart of the Cognition Therapeutics, Inc. price trend over the selected period. The price fell overall, ranging from 0.72 to 0.74, ending at 0.73.
$0.72$0.74
L
Show Current Price
H

Cognition Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$53.45M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.18
Revenue (TTM)
$0.00
Return On Equity (TTM)
-50.80%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
20.28%

Cognition Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$4.93-$3.34-$4.57-$3.93
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A32.25%-36.83%14.00%

Cognition Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$21.40-$25.79-$33.97-$23.49
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-20.51%-31.72%30.85%

About Cognition Therapeutics, Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Cognition Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$0.94
$0.73
-24.38%
Sep 2026
$1.02
$0.96
-11.11%
Aug 2026
$0.90
$1.08
+21.21%
Jul 2026
$1.19
$0.89
-22.52%
Jun 2026
$1.17
$1.15
-3.36%
May 2026
$1.26
$1.19
-5.93%
Apr 2026
$0.83
$1.26
+67.11%
Mar 2026
$1.07
$0.76
-30.23%
Feb 2026
$1.13
$1.08
+0.46%
Jan 2026
$1.40
$1.08
-19.40%
Dec 2025
$1.74
$1.34
-22.32%
Nov 2025
$1.76
$1.73
-3.90%

CGTX Share Price FAQs